Over the past two decades, BPC-157 has become one of the most studied peptides in the repair and recovery research space, with over 100 published studies exploring its effects across a wide range of tissue types
The analysis of neuron density further supports these findings, with the model group showing a marked reduction in neuron density (Figure 8C), reflecting the adverse effects of sleep deprivation on neuronal health
Protocol adjustments Increasing dosing: If healing slower than expected or pain not improving after 4-6 weeks, consider increasing dose 25-50%
Its not approved by the FDA, its banned by WADA for athletes, and its showing up on military do not use lists
NAD+ metabolism: bioenergetics, signaling and manipulation for therapy
Its compounding-pathway status shifted in April 2026 when the FDA removed it from Category 2 of the 503A bulk substances list, though this is a compounding determination, not an approval